OBJECTIVES: To study mortality in African children born to HIV-1-infected mothers exposed peripartum to zidovudine. METHODS: A randomized placebo-controlled trial in Abidjan and Bobo-Dioulasso. Pregnant women received either 300 mg zidovudine twice daily from 36-38 weeks' gestation, 600 mg during labour, and 300 mg twice daily for 7 days post-partum or a matching placebo. Determinants of mortality were studied up to 18 months, overall and among the infected children: treatment, centre, timing of infection, mother and child HIV disease. RESULTS: There were 75 infant deaths among 407 live births. The risk of death at 18 months was 176/1000 in the zidovudine arm and 221 for placebo. Relative hazard (RH, zidovudine versus placebo) was 0.47 [95% confidence interval (CI) 0.2-1.0] up to 230 days of life. Maternal CD4 lymphocyte count < 200/mm3 (RH 2.92; CI 1.4-6.1) and child HIV-1 infection (RH 12.6; CI 6.6-24.3) increased mortality of all children born to HIV-1-infected mothers. There were 101 children infected (40 in the zidovudine group), and 51 died. Their 18 month probability of death was 590/1000 in the zidovudine group and 510 in the placebo group. Among infected children, maternal zidovudine reduced the risk of death on or before day 230 (RH 0.18; CI 0.1-0.5). Maternal CD4 lymphocyte count < 200/mm3 (RH 3.25; CI 1.3-8.4), maternal death (RH 9.65; CI 1.7-56.0), diagnosis of paediatric infection on or before day 12 (RH 18.1; CI 4.8-69.0) and between days 13 and 45 (RH 7.63; CI 2.0-29.5), clinical paediatric AIDS (RH 5.37; CI 2.3-12.7) were risk factors for death in HIV-1-infected children. CONCLUSION: Mother-to-child transmission reduction by zidovudine is safe and beneficial to African children. The mortality of HIV-1-infected children is high. Peripartum maternal zidovudine exerts a protective effect for at least 8 months.
RCT Entities:
OBJECTIVES: To study mortality in African children born to HIV-1-infected mothers exposed peripartum to zidovudine. METHODS: A randomized placebo-controlled trial in Abidjan and Bobo-Dioulasso. Pregnant women received either 300 mg zidovudine twice daily from 36-38 weeks' gestation, 600 mg during labour, and 300 mg twice daily for 7 days post-partum or a matching placebo. Determinants of mortality were studied up to 18 months, overall and among the infected children: treatment, centre, timing of infection, mother and childHIV disease. RESULTS: There were 75 infant deaths among 407 live births. The risk of death at 18 months was 176/1000 in the zidovudine arm and 221 for placebo. Relative hazard (RH, zidovudine versus placebo) was 0.47 [95% confidence interval (CI) 0.2-1.0] up to 230 days of life. Maternal CD4 lymphocyte count < 200/mm3 (RH 2.92; CI 1.4-6.1) and childHIV-1 infection (RH 12.6; CI 6.6-24.3) increased mortality of all children born to HIV-1-infected mothers. There were 101 children infected (40 in the zidovudine group), and 51 died. Their 18 month probability of death was 590/1000 in the zidovudine group and 510 in the placebo group. Among infected children, maternal zidovudine reduced the risk of death on or before day 230 (RH 0.18; CI 0.1-0.5). Maternal CD4 lymphocyte count < 200/mm3 (RH 3.25; CI 1.3-8.4), maternal death (RH 9.65; CI 1.7-56.0), diagnosis of paediatric infection on or before day 12 (RH 18.1; CI 4.8-69.0) and between days 13 and 45 (RH 7.63; CI 2.0-29.5), clinical paediatric AIDS (RH 5.37; CI 2.3-12.7) were risk factors for death in HIV-1-infectedchildren. CONCLUSION: Mother-to-child transmission reduction by zidovudine is safe and beneficial to African children. The mortality of HIV-1-infectedchildren is high. Peripartum maternal zidovudine exerts a protective effect for at least 8 months.
Authors: Christine M Rousseau; Ruth W Nduati; Barbra A Richardson; Matthew S Steele; Grace C John-Stewart; Dorothy A Mbori-Ngacha; Joan K Kreiss; Julie Overbaugh Journal: J Infect Dis Date: 2003-02-18 Impact factor: 5.226
Authors: Milly Marston; Renaud Becquet; Basia Zaba; Lawrence H Moulton; Glenda Gray; Hoosen Coovadia; Max Essex; Didier K Ekouevi; Debra Jackson; Anna Coutsoudis; Charles Kilewo; Valériane Leroy; Stefan Wiktor; Ruth Nduati; Philippe Msellati; François Dabis; Marie-Louise Newell; Peter D Ghys Journal: Int J Epidemiol Date: 2011-01-18 Impact factor: 7.196
Authors: Dwight E Yin; Meredith G Warshaw; William C Miller; Hannah Castro; Susan A Fiscus; Lynda M Harper; Linda J Harrison; Nigel J Klein; Joanna Lewis; Ann J Melvin; Gareth Tudor-Williams; Ross E McKinney Journal: Pediatrics Date: 2014-10 Impact factor: 7.124
Authors: Elizabeth M Obimbo; Dorothy A Mbori-Ngacha; James O Ochieng; Barbra A Richardson; Phelgona A Otieno; Rose Bosire; Carey Farquhar; Julie Overbaugh; Grace C John-Stewart Journal: Pediatr Infect Dis J Date: 2004-06 Impact factor: 2.129
Authors: L Mandelbrot; P Msellati; N Meda; V Leroy; R Likikouët; P Van de Perre; L Dequae-Merchadoux; F Sylla-Koko; A Ouangre; T Ouassa; R Ramon; L Gautier-Charpentier; M Cartoux; M Dosso; F Dabis; C Welffens-Ekra Journal: Sex Transm Infect Date: 2002-08 Impact factor: 3.519